Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Ambrx Biopharma rises 8.2% » 10:00
08/02/21
08/02
10:00
08/02/21
10:00
AMAM

Ambrx Biopharma

$20.95 /

+1.75 (+9.11%)

Ambrx Biopharma is up…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
AMAM Ambrx Biopharma
$20.95 /

+1.75 (+9.11%)

AMAM Ambrx Biopharma
$20.95 /

+1.75 (+9.11%)

07/13/21 Cowen
Cowen starts Ambrx at Outperform on 'promising' ARX788 data
07/13/21 BofA
BofA starts Ambrx Biopharma at Buy with $26 price target
07/13/21 Cowen
Ambrx Biopharma initiated with an Outperform at Cowen
07/13/21 BofA
Ambrx Biopharma initiated with a Buy at BofA
  • 18
    Jun
AMAM Ambrx Biopharma
$20.95 /

+1.75 (+9.11%)

Hot Stocks
Ambrx Biopharma rises 7.7% » 09:47
08/02/21
08/02
09:47
08/02/21
09:47
AMAM

Ambrx Biopharma

$21.05 /

+1.85 (+9.64%)

Ambrx Biopharma is up…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
AMAM Ambrx Biopharma
$21.05 /

+1.85 (+9.64%)

AMAM Ambrx Biopharma
$21.05 /

+1.85 (+9.64%)

07/13/21 Cowen
Cowen starts Ambrx at Outperform on 'promising' ARX788 data
07/13/21 BofA
BofA starts Ambrx Biopharma at Buy with $26 price target
07/13/21 Cowen
Ambrx Biopharma initiated with an Outperform at Cowen
07/13/21 BofA
Ambrx Biopharma initiated with a Buy at BofA
  • 18
    Jun
AMAM Ambrx Biopharma
$21.05 /

+1.85 (+9.64%)

Over a week ago
Hot Stocks
Ambrx Biopharma rises 7.6% » 12:00
07/19/21
07/19
12:00
07/19/21
12:00
AMAM

Ambrx Biopharma

$20.85 /

+0.79 (+3.94%)

Ambrx Biopharma is up…

Ambrx Biopharma is up 7.6%, or $1.49 to $21.05.

ShowHide Related Items >><<
AMAM Ambrx Biopharma
$20.85 /

+0.79 (+3.94%)

AMAM Ambrx Biopharma
$20.85 /

+0.79 (+3.94%)

07/13/21 Cowen
Cowen starts Ambrx at Outperform on 'promising' ARX788 data
07/13/21 BofA
BofA starts Ambrx Biopharma at Buy with $26 price target
07/13/21 Cowen
Ambrx Biopharma initiated with an Outperform at Cowen
07/13/21 BofA
Ambrx Biopharma initiated with a Buy at BofA
  • 18
    Jun
AMAM Ambrx Biopharma
$20.85 /

+0.79 (+3.94%)

Hot Stocks
Ambrx Biopharma rises 8.4% » 10:00
07/19/21
07/19
10:00
07/19/21
10:00
AMAM

Ambrx Biopharma

$21.00 /

+0.94 (+4.69%)

Ambrx Biopharma is up…

Ambrx Biopharma is up 8.4%, or $1.64 to $21.20.

ShowHide Related Items >><<
AMAM Ambrx Biopharma
$21.00 /

+0.94 (+4.69%)

AMAM Ambrx Biopharma
$21.00 /

+0.94 (+4.69%)

07/13/21 Cowen
Cowen starts Ambrx at Outperform on 'promising' ARX788 data
07/13/21 BofA
BofA starts Ambrx Biopharma at Buy with $26 price target
07/13/21 Cowen
Ambrx Biopharma initiated with an Outperform at Cowen
07/13/21 BofA
Ambrx Biopharma initiated with a Buy at BofA
  • 18
    Jun
AMAM Ambrx Biopharma
$21.00 /

+0.94 (+4.69%)

Hot Stocks
Ambrx Biopharma falls -13.6% » 12:00
07/15/21
07/15
12:00
07/15/21
12:00
AMAM

Ambrx Biopharma

$18.87 /

-3.25 (-14.69%)

Ambrx Biopharma is down…

Ambrx Biopharma is down -13.6%, or -$3.00 to $19.00.

ShowHide Related Items >><<
AMAM Ambrx Biopharma
$18.87 /

-3.25 (-14.69%)

AMAM Ambrx Biopharma
$18.87 /

-3.25 (-14.69%)

07/13/21 Cowen
Cowen starts Ambrx at Outperform on 'promising' ARX788 data
07/13/21 BofA
BofA starts Ambrx Biopharma at Buy with $26 price target
07/13/21 Cowen
Ambrx Biopharma initiated with an Outperform at Cowen
07/13/21 BofA
Ambrx Biopharma initiated with a Buy at BofA
  • 18
    Jun
AMAM Ambrx Biopharma
$18.87 /

-3.25 (-14.69%)

Initiation
Cowen starts Ambrx at Outperform on 'promising' ARX788 data » 08:52
07/13/21
07/13
08:52
07/13/21
08:52
AMAM

Ambrx Biopharma

$21.52 /

-0.15 (-0.69%)

Cowen analyst Phil Nadeau…

Cowen analyst Phil Nadeau initiated coverage of Ambrx Biopharma with an Outperform rating and no price target. The company is developing engineered therapeutic proteins with synthetic amino acids to enable precision conjugation, Nadeau tells investors in a research note. The analyst believes Ambrx will create "much shareholder value" as ARX788 advances and other pipeline products mature. He says ARX788 has produced "promising" clinical data in breast and gastric cancers.

ShowHide Related Items >><<
AMAM Ambrx Biopharma
$21.52 /

-0.15 (-0.69%)

AMAM Ambrx Biopharma
$21.52 /

-0.15 (-0.69%)

07/13/21 BofA
BofA starts Ambrx Biopharma at Buy with $26 price target
07/13/21 Cowen
Ambrx Biopharma initiated with an Outperform at Cowen
07/13/21 BofA
Ambrx Biopharma initiated with a Buy at BofA
07/13/21 Goldman Sachs
Ambrx Biopharma initiated with a Buy at Goldman Sachs
  • 18
    Jun
AMAM Ambrx Biopharma
$21.52 /

-0.15 (-0.69%)

Initiation
BofA starts Ambrx Biopharma at Buy with $26 price target » 07:50
07/13/21
07/13
07:50
07/13/21
07:50
AMAM

Ambrx Biopharma

$21.52 /

-0.15 (-0.69%)

As previously reported,…

As previously reported, BofA analyst Tazeen Ahmad initiated coverage of Ambrx Biopharma with a Buy rating and $26 price target. The company is building a pipeline of oncology therapeutics, with an initial focus on antibody-drug conjugates, or ADCs, Ahmad tells investors. Lead asset ARX788 is targeting HER2 and while Ahmad said the HER2+ space is "crowded with approved and pipeline therapies," the analyst also sees undermet need in the space and added that clinical data to-date support a potential safety advantage for '788.

ShowHide Related Items >><<
AMAM Ambrx Biopharma
$21.52 /

-0.15 (-0.69%)

AMAM Ambrx Biopharma
$21.52 /

-0.15 (-0.69%)

07/13/21 Cowen
Ambrx Biopharma initiated with an Outperform at Cowen
07/13/21 BofA
Ambrx Biopharma initiated with a Buy at BofA
07/13/21 Goldman Sachs
Ambrx Biopharma initiated with a Buy at Goldman Sachs
  • 18
    Jun
AMAM Ambrx Biopharma
$21.52 /

-0.15 (-0.69%)

Initiation
Ambrx Biopharma initiated with an Outperform at Cowen » 06:08
07/13/21
07/13
06:08
07/13/21
06:08
AMAM

Ambrx Biopharma

$21.52 /

-0.15 (-0.69%)

Cowen analyst Phil Nadeau…

Cowen analyst Phil Nadeau initiated coverage of Ambrx Biopharma with an Outperform rating.

ShowHide Related Items >><<
AMAM Ambrx Biopharma
$21.52 /

-0.15 (-0.69%)

AMAM Ambrx Biopharma
$21.52 /

-0.15 (-0.69%)

07/13/21 BofA
Ambrx Biopharma initiated with a Buy at BofA
07/13/21 Goldman Sachs
Ambrx Biopharma initiated with a Buy at Goldman Sachs
  • 18
    Jun
AMAM Ambrx Biopharma
$21.52 /

-0.15 (-0.69%)

Initiation
Ambrx Biopharma initiated with a Buy at BofA » 06:04
07/13/21
07/13
06:04
07/13/21
06:04
AMAM

Ambrx Biopharma

$21.52 /

-0.15 (-0.69%)

BofA initiated coverage…

BofA initiated coverage of Ambrx Biopharma with a Buy rating and $26 price target.

ShowHide Related Items >><<
AMAM Ambrx Biopharma
$21.52 /

-0.15 (-0.69%)

AMAM Ambrx Biopharma
$21.52 /

-0.15 (-0.69%)

07/13/21 Goldman Sachs
Ambrx Biopharma initiated with a Buy at Goldman Sachs
  • 18
    Jun
AMAM Ambrx Biopharma
$21.52 /

-0.15 (-0.69%)

Initiation
Ambrx Biopharma initiated with a Buy at Goldman Sachs » 04:44
07/13/21
07/13
04:44
07/13/21
04:44
AMAM

Ambrx Biopharma

$21.52 /

-0.15 (-0.69%)

Goldman Sachs analyst…

Goldman Sachs analyst Graig Suvannavejh initiated coverage of Ambrx Biopharma with a Buy rating and $53 price target. The company's s lead candidate ARX788, an anti-HER2 antibody-drug conjugate in a pivotal Phase 2/3 trial for breast cancer, has the ability to differentiate versus other anti-HER2 ADCs, Suvannavejh tells investors in a research note. The analyst says the early data on both efficacy and safety have been encouraging.

ShowHide Related Items >><<
AMAM Ambrx Biopharma
$21.52 /

-0.15 (-0.69%)

  • 18
    Jun
AMAM Ambrx Biopharma
$21.52 /

-0.15 (-0.69%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.